The pedunculopontine nucleus (PPN) is located in the dorso-lateral part of
the ponto-mesencephalic tegmentum. The PPN is composed of two groups of neu
rons: one containing acetylcholine, and the other containing non-cholinergi
c neurotransmitters (GABA, glutamate). The PPN is connected reciprocally wi
th the limbic system, the basal ganglia nuclei (globus pallidus, substantia
nigra, subthalamic nucleus), and the brainstem reticular formation. The ca
udally directed corticolimlic-ventral striatal-ventral pallidal-PPN-pontome
dullary reticular nuclei-spinal cord pathway seems to be involved in the in
itiation, acceleration, deceleration, and termination of locomotion. This p
athway is under the control of the deep cerebellar and basal ganglia nuclei
at the level of the PPN, particularly via potent inputs from the medial gl
obus pallidus, substantia nigra pars reticulata and subthalamic nucleus. Th
e PPN sends profuse ascending cholinergic efferent fibers to almost all the
thalamic nuclei, to mediate phasic events in rapid-eye-movement sleep. Exp
erimental evidence suggests that the PPN, along with other brain stem nucle
i, is also involved in anti-nociception and startle reactions. In idiopathi
c Parkinson's disease (IPD) and parkinson plus syndrome, overactive pallida
l and nigral inhibitory inputs to the PPN may cause sequential occurrences
of PPN hypofunction, decreased excitatory PPN input to the substantia nigra
, and aggravation of striatal dopamine deficiency. In addition, neuronal lo
ss in the PPN itself may cause dopamine-resistant parkinsonian deficits, in
cluding gait disorders, postural instability and sleep disturbances. In pat
ients with IPD, such deficits may improve after posteroventral pallidotomy,
but not after thalamotomy. One of the possible explanations for such diffe
rences is that dopamine-resistant parkinsonian deficits are mediated to the
PPN by the descending pallido-PPN inhibitory fibers, which leave the palli
do-thalamic pathways before they reach the thalamic targets.